---
title: 'Supportive care for systemic amyloidosis: International Society of Amyloidosis
  (ISA) expert panel guidelines'
date: '2025-02-22'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39985185/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20250223170750&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: Systemic amyloidosis refers to a group of protein misfolding disorders
  resulting in organ deposition with amyloid, leading to organ dysfunction, ultimately
  resulting in organ failure and death if not successfully treated. Treatment is type-specific
  and aimed at the underlying source of the misfolded protein. In the past decades,
  treatments have become increasingly available across the various amyloidosis types
  with improved response rates and longer survival. Supportive care measures are ...
disable_comments: true
---
Systemic amyloidosis refers to a group of protein misfolding disorders resulting in organ deposition with amyloid, leading to organ dysfunction, ultimately resulting in organ failure and death if not successfully treated. Treatment is type-specific and aimed at the underlying source of the misfolded protein. In the past decades, treatments have become increasingly available across the various amyloidosis types with improved response rates and longer survival. Supportive care measures are ...